Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 299-305

  Holme, Ingar ^a   Aastveit, Are H ^b   Hammar, Niklas ^c,d   Jungner, Ingmar ^c   Walldius, Göran ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Acute myocardial infarction; Apolipoproteins; Heart failure; Inflammation; Ischemic stroke; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; STROKE; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; ISCHEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STROKE;

EID: 77958497193     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.049     Document Type: Article

References (30)

1. Marcovina S.M., Crea F., Davignon J., et al. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. Review. J Intern Med 2007, 261:214-234.
2. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
3. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. J Am Med Assoc 2009, 302:49-57.
4. Rana J.S., Boekholt S.M., Ridker P.M., et al. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med 2007, 262:678-689.
5. Li C., Engström G., Hedblad B. Leukocyte count is associated with incidence of coronary events, but not with stroke: a prospective cohort study. Atherosclerosis 2010, 209:545-550.
6. Turner S.J., Ketch T.R., Gandhi S.K., Sane D.C. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 2008, 155:806-816.
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43 [Correction: N Engl J Med 2000;343:512].
8. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
9. Andersson J., Sundström J., Kurland L., et al. The carotid artery plaque size and echogenecity are related to different cardiovascular risk factors in the elderly. Lipids 2009, 44:397-403.
10. Watanabe J., Grijalva V., Hama S., et al. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1 containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009, 284:18292-18301.
11. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Haptoglobin and risk of myocardial infarction, stroke and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Ann Med 2009, 41:522-532.
12. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009, 266:558-570.
13. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
14. Holme I., Aastveit A.H., Jungner I., Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008, 264:30-38.
15. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MORtality RISk study (AMORIS). J Intern Med 2009, 265:275-287.
16. Medin J., Nordlund A., Ekberg K. Increasing stroke incidence in Sweden between 1989 and 2000 among persons aged 30 to 65 years: evidence from the Swedish Hospital Discharge Register. Stroke 2004, 35:1047-1051.
17. Hammar N., Alfredsson L., Rosén M., et al. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001, 30(Suppl 1):S30-34.
18. Jungner I., Walldius G., Holme I., Kolar W., Steiner E. Apolipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J Clin Lab Res 1992, 21:247-255.
19. Jungner I., Marcovina S.M., Walldius G., et al. Apolipoprotein B and A-1 values in 147 576 Swedish males and females, standardized according to the World Health Organization - International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998, 44:1641-1649.
20. Talmud P.J., Hawe E., Miller G.J., Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002, 22:1918-1923.
21. Lundberg M., Fredlund P., Hallqvist J., Diderichsen F. A SAS program calculating three measures of interaction with confidence intervals. Epidemiology 1996, 7:655-656.
22. Rothman K.J. The estimation of synergy and antagonism. Am J Epidemiol 1976, 103(5):506-511.
23. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
24. Engström G., Lind P., Hedblad B., et al. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002, 105:2632-2637.
25. Ridker P.M. C-Reactive Protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 2009, 55:209-215.
26. Kocaman S.A., Sahinarslan A., Cemri M., et al. Independent relationship of serum uric acid levels with leukocytes and coronary atherosclerotic burden. Nutr Metab Cardiovasc Dis 2009, 19:729-735.
27. The Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
28. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38:217-231.
29. Rifai N., Ridker P.M. High-sensitivity C-Reactive Protein: a novel and promising marker of coronary heart disease. Clin Chem 2001, 47:403-411.
30. Kümler T., Gislason G.H., Kirk V., et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008, 10:658-660.